Literature DB >> 17544998

Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease.

Kianoosh Katchar1, Claribel P Taylor, Sanjeev Tummala, Xinhua Chen, Javed Sheikh, Ciarán P Kelly.   

Abstract

BACKGROUND & AIMS: Individuals who mount a significant serum immunoglobulin (Ig)G response to toxin A are protected against recurrent Clostridium difficile-associated disease (CDAD). We investigated whether humoral immune deficiencies and/or specific IgG subclass responses are associated with recurrent CDAD.
METHODS: We compared the clinical characteristics and humoral immune responses of 13 patients with recurrent CDAD with 13 matched controls with a single CDAD episode. We measured the serum IgG titers to tetanus and diphtheria toxoids, as well as total and toxin A- and toxin B-specific serum IgG, IgA, and IgG subclass concentrations.
RESULTS: There were no differences between the single and recurrent CDAD subjects in terms of age, sex, ethnicity, or other potential confounding variables. The total duration of diarrhea in patients with recurrent CDAD was greater (median, 62 vs 17 days; P = .005). IgG titers to tetanus and diphtheria toxoids, total IgG, and IgG subclass levels were similar in both groups. The total IgA was somewhat lower in those with recurrent CDAD (204 vs 254 mg/dL; P = .05). IgA, IgG, IgG1, and IgG4 anti-toxin A and anti-toxin B levels were similar in both groups. However, IgG2 and IgG3 anti-toxin A levels were significantly lower in the recurrent group (P = .01 and .001, respectively).
CONCLUSIONS: Subjects with recurrent CDAD did not show evidence of widespread humoral immune deficiency or of IgG subclass deficiency. Their low serum IgG anti-toxin A concentrations reflected selectively reduced IgG2 and IgG3 subclass responses. Measurement of specific IgG2/3 anti-toxin A may be useful in selecting patients for treatment with agents to prevent recurrent CDAD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17544998     DOI: 10.1016/j.cgh.2007.02.025

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  20 in total

Review 1.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

2.  An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.

Authors:  Scott M Baliban; Amanda Michael; Berje Shammassian; Shikata Mudakha; Amir S Khan; Simon Cocklin; Isaac Zentner; Brian P Latimer; Laurent Bouillaut; Meredith Hunter; Preston Marx; Niranjan Y Sardesai; Seth L Welles; Jeffrey M Jacobson; David B Weiner; Michele A Kutzler
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

Review 3.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

Review 4.  Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA.

Authors:  Kang Chen; Giuliana Magri; Emilie K Grasset; Andrea Cerutti
Journal:  Nat Rev Immunol       Date:  2020-02-03       Impact factor: 53.106

5.  A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.

Authors:  Haiying Wang; Xingmin Sun; Yongrong Zhang; Shan Li; Kevin Chen; Lianfa Shi; Weijia Nie; Raj Kumar; Saul Tzipori; Jufang Wang; Tor Savidge; Hanping Feng
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

6.  Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.

Authors:  Michelle Hughes; Taha Qazi; Adam Berg; Janice Weinberg; Xinhua Chen; Ciaran P Kelly; Francis A Farraye
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

7.  Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Authors:  Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

8.  Protective efficacy induced by recombinant Clostridium difficile toxin fragments.

Authors:  Rosanna Leuzzi; Janice Spencer; Anthony Buckley; Cecilia Brettoni; Manuele Martinelli; Lorenza Tulli; Sara Marchi; Enrico Luzzi; June Irvine; Denise Candlish; Daniele Veggi; Werner Pansegrau; Luigi Fiaschi; Silvana Savino; Erwin Swennen; Osman Cakici; Ernesto Oviedo-Orta; Monica Giraldi; Barbara Baudner; Nunzia D'Urzo; Domenico Maione; Marco Soriani; Rino Rappuoli; Mariagrazia Pizza; Gillian R Douce; Maria Scarselli
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

9.  Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.

Authors:  Zhiyong Yang; Lianfa Shi; Hua Yu; Yongrong Zhang; Kevin Chen; Ashley Saint Fleur; Guang Bai; Hanping Feng
Journal:  Pathog Dis       Date:  2016-08-07       Impact factor: 3.166

Review 10.  The host immune response to Clostridium difficile infection.

Authors:  Katie Solomon
Journal:  Ther Adv Infect Dis       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.